Naltrexone augmented with prazosin for alcohol use disorder: results from a randomized controlled proof-of-concept trial

Naltrexone and nalmefene are both opioid receptor antagonists used to reduce alcohol consumption. They look nearly identical on paper — same drug class, similar mechanism, similar indication — and in many clinical contexts, they’ve been treated as largely interchangeable choices in a modest medication toolkit for alcohol use disorder. A January 2026 study published in PubMed disrupts that picture in a way that matters for how we prescribe.

The study found that naltrexone and nalmefene do not work the same way. They work via “selective efficacy in subpopulations distinguished by behavioral and blood-based biomarkers” — which means different patients respond to different drugs, and the biomarkers that predict which patient will respond to which drug are now, for the first time, partly identified. This is precision medicine for alcohol use disorder, a field that has long operated on trial and error.

The biochemistry underneath the difference

The mechanism distinction between the two drugs has been known at the receptor level for years: naltrexone is a pure antagonist at the kappa opioid receptor, while nalmefene acts as a partial agonist at the same receptor. The kappa opioid receptor is implicated in the stress and dysphoria components of alcohol use — what drives people to drink not for pleasure but to relieve a negative emotional state, what pharmacologists call “negative reinforcement drinking.” The distinction between how these two drugs bind to kappa receptors turns out to predict something real about clinical outcomes.

Patients with higher baseline levels of kappa opioid receptor activity — a state that tends to manifest behaviorally as higher sensitivity to stress-induced craving and reward valuation shifts — appear to respond better to one drug than the other. The 2026 biomarker study used blood-based measures alongside behavioral assessments to stratify these subpopulations, and the differentiation held in its sample. The implications are straightforward: if you can take a blood draw and predict whether a patient will respond to naltrexone or nalmefene before you prescribe, you dramatically reduce the clinical dead time of “let’s try this and see.”

What race and sex data adds to the picture

A secondary analysis published in PMC in early 2026 examined a prior extended-release naltrexone randomized controlled trial for alcohol use disorder and found significant differences in response across race, ethnicity, and sex. Black patients and women showed different response profiles from the primary population in the original trial — a common finding in secondary analyses that reexamines older RCTs, and a consistent reminder that the evidence base for addiction medicine was largely built on studies that enrolled mostly white men and generalized from there.

These findings don’t overturn the evidence for naltrexone. They narrow it. They say: naltrexone works, and it works differently in different people, and the field now has enough data to start asking why rather than averaging across the difference. This is the kind of second-generation research that turns a class of drugs from a tool into a set of tools — each with a clearer indication and a clearer population.

Augmentation: naltrexone and prazosin together

A proof-of-concept RCT published in Alcohol and Alcoholism examined whether adding prazosin — an alpha-1 adrenergic antagonist used primarily for hypertension and PTSD — to naltrexone produced better outcomes than naltrexone alone. The trial was small and designated proof-of-concept, which means it wasn’t powered to show efficacy, only to show whether the combination was safe and whether the signal was there. The signal was there. Prazosin targets the noradrenergic stress response that underlies craving in the negative-reinforcement drinking population — the same population that the kappa receptor research suggests might respond differently to nalmefene. Whether prazosin augmentation and nalmefene are addressing the same underlying phenotype through different mechanisms, or addressing different phenotypes, is the kind of question that a biomarker framework can now start to answer.

What this means for clinical practice

Alcohol use disorder is the second-leading cause of drug overdose death in the United States — though it rarely gets framed that way because alcohol deaths are rarely counted in the same overdose category as fentanyl deaths. The treatment gap for AUD is comparable to the treatment gap for opioid use disorder: millions of people who drink at harmful or dependent levels and don’t receive medication because medication isn’t offered, or because what was offered didn’t work and nothing else was tried.

The 2026 biomarker research doesn’t immediately change what’s available. Nalmefene is approved in Europe but not the United States for alcohol use disorder, though it’s available off-label. Naltrexone is both FDA-approved and significantly underprescribed. The research changes the conversation about precision: it gives clinicians a reason to think carefully about which patient gets which drug, rather than defaulting to one (usually naltrexone) and moving on if it doesn’t work. For the patient whose kappa receptor profile makes them a nalmefene responder — or a prazosin-plus-naltrexone responder — the biomarker research represents the first evidence that personalized prescribing might be within reach. That is a meaningful shift in a field where, for too long, the answer to “why isn’t my medication working?” has been “we don’t really know.”

That is a meaningful shift in a field where, for too long, the answer to “why isn’t my medication working?” has been “we don’t really know.”